Abeona Therapeutics (ABEO) Stifel Virtual Cell Therapy Forum summary
Event summary combining transcript, slides, and related documents.
Stifel Virtual Cell Therapy Forum summary
8 Jul, 2026Company overview and lead program
Transitioning from R&D to commercial stage with a clear path to profitability.
Lead program pz-cel targets recessive dystrophic epidermolysis bullosa (RDEB), a severe connective tissue disorder.
Pz-cel is an autologous engineered cell therapy designed to restore collagen VII and promote durable wound healing.
Clinical studies show sustained wound healing and pain reduction for years after a single treatment.
Additional pipeline includes preclinical AAV-based gene therapies for ophthalmology and partnered programs.
Clinical data and differentiation
Phase I/IIa and pivotal Phase III studies demonstrate significant wound healing in chronic, large wounds unresponsive for years.
Treated wounds showed no spontaneous healing in control arms, highlighting the therapy's impact.
Efficacy observed across multiple anatomical locations, with potential label expansion beyond toughest wounds.
No squamous cell carcinomas observed in treated sites, though data is not yet statistically robust.
Registry data will be collected post-launch to further monitor long-term outcomes.
Safety and regulatory status
Gamma-retroviral vector used for gene integration; no replication-competent retrovirus detected in over 120 monitored samples.
Literature and clinical experience suggest extremely low risk of insertional oncogenesis.
Risk-benefit profile considered favorable given the high baseline risk of squamous cell carcinoma in RDEB.
No efficacy or safety concerns raised in the recent Complete Response Letter (CRL); focus is on manufacturing and assay validation.
Latest events from Abeona Therapeutics
- A 12.49 million-share resale shelf follows the ABO-801 acquisition and $30 million private placement.ABEO
Registration filing - ZEVASKYN launch ramp leads, with ABO-801 and partnered-program catalysts ahead.ABEO
Jefferies Global Healthcare Conference - ABO-801 adds a redesigned EoE Phase III program alongside ZEVASKYN’s expanding launch.ABEO
Stifel 2026 Healthcare Conference 2026 - Strong histologic results; exploratory DSQ mapping informs symptom endpoint strategy.ABEO
Clinical Development History presentation - ZEVASKYN’s $11.4M Q2 revenue anchors a broader cell- and gene-therapy pipeline.ABEO
Corporate presentation - ZEVASKYN revenue rose 18% QoQ as ABO-801 advanced toward Phase III.ABEO
Q3 2026 - ZEVASKYN launch accelerates with rising revenue, broad access, and a robust pipeline of gene therapies.ABEO
H.C. Wainwright 28th Annual Global Investment Conference - Durable gene therapy launch advances with expanding treatment centers and strong patient access.ABEO
Morgan Stanley 24th Annual Global Healthcare Conference - Steady ZEVASKYN rollout, robust coverage, and pipeline advances set stage for strong future growth.ABEO
12th Annual Cantor Fitzgerald Global Healthcare Conference - Q2 2026 ZEVASKYN revenue up 31% to $11.4M, NTAP status secured, net loss $20.2M, cash $146.8M.ABEO
Q2 2026